Abstract
No public abstract is available from the verified source records.
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease
10.1136/thorax.57.10.847 · 2002
Susceptibility to exacerbation in chronic obstructive pulmonary disease
10.1056/nejmoa0909883 · 2010
Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort
10.1378/chest.14-0655 · 2015
Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort
10.1183/13993003.01339-2020 · 2021
Impact and prevention of severe exacerbations of COPD: a review of the evidence
10.2147/copd.s139470 · 2017
A 4-year trial of tiotropium in chronic obstructive pulmonary disease
10.1056/nejmoa0805800 · 2008
Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials
10.1016/s2213-2600(24)00409-0 · 2025
Prognostic risk factors for moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease: a systematic literature review
10.1186/s12931-022-02123-5 · 2022
Cardiovascular and mortality risks following COVID-19-related vs. non-COVID COPD exacerbations
10.1093/annalsats/aaoag084 · 2026
Cardiovascular consequences of viral infections: from COVID to other viral diseases
10.1093/cvr/cvab315 · 2021
No additional external references are available.